Tofflon’s Platform For Vaccines

Mr. VIKRANT TIRATHKUMAR HEDAU
Tofflon Science and Technology Group Co., Ltd.
Development Milestones

01  1993  Shanghai Tofflon Founded
02  2011  IPO on Shenzhen Stock Exchange
03  2021  Tofflon Science and Technology Group Co., Ltd.
04  FUTURE  Global Tofflon
India Operations

Fabrication Facility

Corporate office

SUS mfg. Facility
Value Embodiment

- 29 years manufacturing experience in pharmaceutic industry
- Supply to more than 48 countries and regions around the world
- Revenue exceed USD 1.25 billion in 2021
- 2000 patents
- 200 software copyrights

- 2800+ serving more than 2,800 pharmaceutical companies worldwide
- 4500+ more than 4500 professionals
- 12000+ more than 12000 sets of machine/ system are distributed all over the world
What We Learn Today and Tomorrow is the Drug Manufacturing Science and Process Equipment Manufacturing Science for the Future of Smart Pharma Factory
DS-SS

Cell vial → Incubation → seed → Production → Depth Filtration → Chrome → Inactivation → UF/DF → Bulk Freeze

- Cell bank
- CO2 incubators
- Wave Bioreactor
- SS Bioreactor / Fermenter
- Depth Filtration skid
- Column: Manual & Autopack & chrome Skid
- Vessel system
- TFF system
- Freeze & Thaw system & Quick freezers
Decontamination Area
Decontamination Solid Waste
Decontamination Liquid Waste
Continuous Bioinactivation system
VHP Pass Box
VHP Generator
Fast-Track Vaccine Development Platform

Be-Hive Incubator system

GMP Cell Processing Full-station System
Complex Biologics Project
Complex Biologics Project
Welcome To Tofflon